Multiple T-cell surface antigens

Multiple T-cell surface antigens on thymocytes represent the collective target of anti-thymocyte globulin (ATG), a polyclonal antibody preparation used for potent immunosuppression. These antigens encompass a wide variety of cell surface proteins, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, and CD45, as well as HLA class I and II molecules (Mohty, 2007; DrugBank). Biologically, these molecules are critical for T-cell activation, signal transduction, and leukocyte adhesion to the endothelium. In clinical medicine, these antigens are targeted to prevent and treat acute organ transplant rejection and to manage severe aplastic anemia by depleting the T-cell population (Gaber et al., 2010). The mechanism of action involves the induction of T-cell depletion through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and the activation of apoptotic pathways (Mohty, 2007). Monitoring the absolute lymphocyte count or specific CD3+ T-cell counts serves as a primary biomarker for assessing the therapeutic efficacy of drugs hitting these targets (FDA, 2017). However, the broad-spectrum nature of targeting multiple antigens simultaneously can lead to significant safety concerns, such as cytokine release syndrome, serum sickness, and an increased risk of opportunistic infections or malignancies (StatPearls, 2023).

Other names

Thymocyte antigensT-lymphocyte surface antigensATG targetsT-cell surface markers

Induction of T-cell depletion via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis, alongside the modulation of T-cell surface receptors involved in activation and adhesion.